Site icon pharmaceutical daily

Global Duchenne Muscular Dystrophy Market Insights, Epidemiology and Forecast 2019-2028 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Duchenne
Muscular Dystrophy – Market Insights, Epidemiology and Market Forecast –
2028” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology as well as the market trends of
Duchenne Muscular Dystrophy in the United States, EU5 (Germany, Spain,
Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs,
market share of the individual therapies, current and forecasted market
size of Duchenne Muscular Dystrophy (DMD) from 2017 to 2028 segmented by
seven major markets.

The report also covers current treatment practice/algorithm, market
drivers, market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.

Geography Covered

Study Period: 2017-2028

Duchenne Muscular Dystrophy Epidemiology

The Duchenne Muscular Dystrophy (DMD) epidemiology division provide the
insights about historical and current patient pool and forecasted trend
for every 7 major countries. It helps to recognize the causes of current
and forecasted trends by exploring numerous studies and views of key
opinion leaders. This part of the report also provides the diagnosed and
treatable patient pool and their trends along with assumptions
undertaken.

The disease epidemiology covered in the report is segmented by diagnosed
prevalent population, age-specific prevalent population,
mutation-specific prevalent population and prevalent population of
associated comorbidities in Duchenne Muscular Dystrophy.

The report also provides the epidemiology trends observed in the 7MM
during the study period, along with the assumptions undertaken. The
calculated data are presented with relevant tables and graphs to give a
clear view of the epidemiology at first sight.

According to the publisher, the prevalent population of Duchenne
Muscular Dystrophy (DMD) was estimated to be 31,432 [7MM] in 2018.
United States accounts for the highest DMD cases, followed by EU5
(Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries
France had the highest prevalent patient population of Duchenne Muscular
Dystrophy, followed by Italy.

Duchenne Muscular Dystrophy Drug Chapters

This segment of the Duchenne Muscular Dystrophy report encloses the
detailed analysis of marketed drugs and late stage (Phase-III) pipeline
drugs. It also helps to understand the clinical trial details,
expressive pharmacological action, agreements and collaborations,
approval and patent details, advantages and disadvantages of each
included drug and the latest news and press releases.

Current standard of care includes the use of corticosteroids to prolong
ambulation and to delay the onset of secondary complications. Early use
of cardioprotective agents, noninvasive positive pressure ventilation,
and other supportive strategies has improved the life expectancy and
health-related quality of life for many young adults with DMD.
Treatments include the standard care for DMD along with the new upcoming
therapeutic strategies including Genetic Therapies, Cell therapy using
muscle precursor cells or stem cells, Membrane stabilization and
upregulation of cytoskeletal proteins and Treatment of secondary
cascades.

Glucocorticoids, more precisely prednisone and deflazacort, form main
drug treatment for DMD. Deflazacort is an oxazoline derivate of
prednisone. Deflazacort shows more bone-sparing and carbohydrate-sparing
properties with less weight-gain effects and improves strength and
function. Therefore, Deflazacort becomes the preferred choice over
prednisone due to limited side effects and the beneficial properties of
muscle sparing and delayed scoliosis progression.

The current US market possess only two approved products namely Emflaza
and Exondys 51 commercialized by Marathon Pharmaceuticals/ PTC
Therapeutics and Sarepta Therapeutics respectively. The recently
approved products are known to capture the current market. Detailed
chapters for all of these drugs, along with the upcoming therapies i.e.,
Golodirsen (SRP-4053, Sarepta Therapeutics), Talditercept alfa (also
known as RO 6206, RO 7239361, BMS-986089), Idebenone (also known as
Catena; CV-2619; Raxone) by Santhera Pharmaceuticals as well as another
promising candidate i.e., Givinostat have been covered in the report.

Duchenne Muscular Dystrophy Market Outlook

The Duchenne Muscular Dystrophy (DMD) market outlook of the report helps
to build the detailed comprehension of the historic, current and
forecasted trend of the market by analyzing the impact of current
therapies on the market, unmet needs, drivers and barriers and demand of
better technology.

This segment gives a through detail of market trend of each marketed
drug and late-stage pipeline therapy by evaluating their impact based on
annual cost of therapy, inclusion and exclusion criteria’s, mechanism of
action, compliance rate, growing need of the market, increasing patient
pool, covered patient segment, expected launch year, competition with
other therapies, brand value, their impact on the market and view of the
key opinion leaders. The calculated market data are presented with
relevant tables and graphs to give a clear view of the market at first
sight.

Treatments include the standard care for DMD along with the new upcoming
therapeutic strategies including Genetic Therapies, Cell therapy using
muscle precursor cells or stem cells, Membrane stabilization and
upregulation of cytoskeletal proteins and Treatment of secondary
cascades. The medical management for Duchenne Muscular Dystrophy (DMD)
comprises several aspects such as Cardiac care, Diet, Exercise,
Respiratory Care, Braces, Spinal curvatures. The treatment strategy is
also encompasses supportive treatment and Psychosocial management. DMD
is a multilevel/multisystem disease. The medical care of a patient who
has DMD and his family is not complete without support for their
psychosocial wellbeing.

According to the publisher, the global market of Duchenne Muscular
Dystrophy (DMD) was estimated to be USD 1,022 million in 2018. The
United States accounts for the largest market size of Duchenne Muscular
Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy,
France, and Spain), and Japan. Among the EU5 countries, France had the
highest market size with 84.15 Million in 2018, while Spain had the
lowest market size of Duchenne Muscular Dystrophy (DMD). The increasing
awareness of the disease assisted by organizational support along with
the promising pipeline therapies is expected to fuel the market size
during the forecasted period of 2019-2028.

Duchenne Muscular Dystrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs
recently launched in the market or will get launched in the market
during the study period from 2017-2028. The analysis covers market
uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake,
reasons behind the maximal use of new drugs and allows the comparison of
the drugs on the basis of market share and size which again will be
useful in investigating factors important in market uptake and in making
financial and regulatory decisions.

Expected Launch of potential therapies may increase market size in the
coming years, assisted by an increase in diagnosed prevalent population
of Duchenne Muscular Dystrophy (DMD). Owing to the positive outcomes of
the several products during the developmental stage by key players such
as Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco etc.
has a potential to create a significant positive shift in the Duchenne
Muscular Dystrophy (DMD) Market Size.

Duchenne Muscular Dystrophy Report Insights

Duchenne Muscular Dystrophy Report Key Strengths

Duchenne Muscular Dystrophy Report Assessment

Key Benefits

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rsmxy

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Musculoskeletal
Disorders Drugs

Exit mobile version